BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011;10 Suppl 2:S29-S36. [PMID: 21658639 DOI: 10.1016/s1569-1993(11)60006-4] [Cited by in Crossref: 233] [Cited by in F6Publishing: 69] [Article Influence: 21.2] [Reference Citation Analysis]
Number Citing Articles
1 Slae M, Wilschanski M. Cystic fibrosis and the gut. Frontline Gastroenterol 2021;12:622-8. [PMID: 34917319 DOI: 10.1136/flgastro-2020-101610] [Reference Citation Analysis]
2 Narkewicz MR. Cystic Fibrosis Liver Disease and Ursodeoxycholic Acid: One Small Step Forward, Miles to Go. J Pediatr 2016;177:17-8. [PMID: 27423176 DOI: 10.1016/j.jpeds.2016.06.020] [Reference Citation Analysis]
3 Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 2017;9:CD000222. [PMID: 28891588 DOI: 10.1002/14651858.CD000222.pub4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
4 Gillespie CD, O'Reilly MK, Allen GN, McDermott S, Chan VO, Ridge CA. Imaging the Abdominal Manifestations of Cystic Fibrosis. Int J Hepatol 2017;2017:5128760. [PMID: 28250993 DOI: 10.1155/2017/5128760] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
5 Joyce S, Carey BW, Moore N, Mullane D, Moore M, McEntee MF, Plant BJ, Maher MM, O'Connor OJ. Computed tomography in cystic fibrosis lung disease: a focus on radiation exposure. Pediatr Radiol 2021;51:544-53. [PMID: 33743038 DOI: 10.1007/s00247-020-04706-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Sadler MD, Crotty P, Fatovich L, Wilson S, Rabin HR, Myers RP. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis. Can J Gastroenterol Hepatol. 2015;29:139-144. [PMID: 25855877 DOI: 10.1155/2015/138530] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
7 Ye W, Narkewicz MR, Leung DH, Karnsakul W, Murray KF, Alonso EM, Magee JC, Schwarzenberg SJ, Weymann A, Molleston JP; CFLDnet research group. Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis. J Pediatr Gastroenterol Nutr 2018;66:122-7. [PMID: 28906321 DOI: 10.1097/MPG.0000000000001728] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
8 Bader RM, Jonas MM, Mitchell PD, Wiggins S, Lee CK. Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis. J Cyst Fibros. 2019;18:280-285. [PMID: 30509601 DOI: 10.1016/j.jcf.2018.11.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Perez LR, Antunes AL, Bonfanti JW, Pinto JB, Roesch EW, Rodrigues D, Dias CA. Detection of methicillin-resistant Staphylococcus aureus in clinical specimens from cystic fibrosis patients by use of chromogenic selective agar. J Clin Microbiol 2012;50:2506-8. [PMID: 22518859 DOI: 10.1128/JCM.00549-12] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
10 Engjom T, Erchinger F, Lærum BN, Tjora E, Gilja OH, Dimcevski G. Ultrasound echo-intensity predicts severe pancreatic affection in cystic fibrosis patients. PLoS One 2015;10:e0121121. [PMID: 25803445 DOI: 10.1371/journal.pone.0121121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
11 Tabori H, Jaudszus A, Arnold C, Mentzel HJ, Lorenz M, Michl RK, Lehmann T, Renz DM, Mainz JG. Relation of Ultrasound Findings and Abdominal Symptoms obtained with the CFAbd-Score in Cystic Fibrosis Patients. Sci Rep 2017;7:17465. [PMID: 29234058 DOI: 10.1038/s41598-017-17302-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
12 Dana J, Girard M, Franchi-Abella S, Berteloot L, Benoit-Cherifi M, Imbert-Bismut F, Sermet-Gaudelus I, Debray D. Comparison of Transient Elastography, ShearWave Elastography, Magnetic Resonance Elastography and FibroTest as routine diagnostic markers for assessing liver fibrosis in children with Cystic Fibrosis. Clin Res Hepatol Gastroenterol 2021;:101855. [PMID: 34933150 DOI: 10.1016/j.clinre.2021.101855] [Reference Citation Analysis]
13 Tabori H, Arnold C, Jaudszus A, Mentzel HJ, Renz DM, Reinsch S, Lorenz M, Michl R, Gerber A, Lehmann T, Mainz JG. Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings. PLoS One 2017;12:e0174463. [PMID: 28472055 DOI: 10.1371/journal.pone.0174463] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 6.4] [Reference Citation Analysis]
14 Karlas T, Neuschulz M, Oltmanns A, Güttler A, Petroff D, Wirtz H, Mainz JG, Mössner J, Berg T, Tröltzsch M, Keim V, Wiegand J. Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. PLoS One 2012;7:e42139. [PMID: 22848732 DOI: 10.1371/journal.pone.0042139] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
15 Drzymała-Czyż S, Krzyżanowska P, Koletzko B, Nowak J, Miśkiewicz-Chotnicka A, Moczko JA, Lisowska A, Walkowiak J. Determinants of Serum Glycerophospholipid Fatty Acids in Cystic Fibrosis. Int J Mol Sci 2017;18:E185. [PMID: 28106773 DOI: 10.3390/ijms18010185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
16 Calvopina DA, Lewindon PJ, Ramm LE, Noble C, Hartel GF, Leung DH, Ramm GA. Gamma-glutamyl transpeptidase-to-platelet ratio as a biomarker of liver disease and hepatic fibrosis severity in paediatric Cystic Fibrosis. J Cyst Fibros 2021:S1569-1993(21)02171-8. [PMID: 34953741 DOI: 10.1016/j.jcf.2021.10.014] [Reference Citation Analysis]
17 Bodewes FA, Bijvelds MJ, de Vries W, Baller JF, Gouw AS, de Jonge HR, Verkade HJ. Cholic acid induces a Cftr dependent biliary secretion and liver growth response in mice. PLoS One 2015;10:e0117599. [PMID: 25680200 DOI: 10.1371/journal.pone.0117599] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
18 Braun C, Bacchetta J, Braillon P, Chapurlat R, Drai J, Reix P. Children and adolescents with cystic fibrosis display moderate bone microarchitecture abnormalities: data from high-resolution peripheral quantitative computed tomography. Osteoporos Int 2017;28:3179-88. [PMID: 28795206 DOI: 10.1007/s00198-017-4179-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
19 Martin CR, Zaman MM, Ketwaroo GA, Bhutta AQ, Coronel E, Popov Y, Schuppan D, Freedman SD. CFTR dysfunction predisposes to fibrotic liver disease in a murine model. Am J Physiol Gastrointest Liver Physiol 2012;303:G474-81. [PMID: 22679000 DOI: 10.1152/ajpgi.00055.2012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
20 Palaniappan SK, Than NN, Thein AW, Moe S, van Mourik I. Interventions for preventing and managing advanced liver disease in cystic fibrosis. Cochrane Database Syst Rev 2017;8:CD012056. [PMID: 28850173 DOI: 10.1002/14651858.CD012056.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
21 Piazza M, Martucci G, Arcadipane A. Postoperative pain management of liver transplantation in cystic fibrosis: Is it time to start US-guided neuraxial blocks? Saudi J Anaesth 2016;10:456-8. [PMID: 27833495 DOI: 10.4103/1658-354X.177343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
22 Nowak JK, Wojsyk-Banaszak I, Mądry E, Wykrętowicz A, Krzyżanowska P, Drzymała-Czyż S, Nowicka A, Pogorzelski A, Sapiejka E, Skorupa W, Szczepanik M, Lisowska A, Walkowiak J. Increased Soluble VCAM-1 and Normal P-Selectin in Cystic Fibrosis: a Cross-Sectional Study. Lung 2017;195:445-53. [PMID: 28646244 DOI: 10.1007/s00408-017-0029-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
23 Fiorotto R, Amenduni M, Mariotti V, Cadamuro M, Fabris L, Spirli C, Strazzabosco M. Animal models for cystic fibrosis liver disease (CFLD). Biochim Biophys Acta Mol Basis Dis 2019;1865:965-9. [PMID: 30071276 DOI: 10.1016/j.bbadis.2018.07.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Gao E, Hercun J, Heller T, Vilarinho S. Undiagnosed liver diseases. Transl Gastroenterol Hepatol 2021;6:28. [PMID: 33824932 DOI: 10.21037/tgh.2020.04.04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021; 13(11): 1727-1742 [PMID: 34904041 DOI: 10.4254/wjh.v13.i11.1727] [Reference Citation Analysis]
26 Scorza M, Elce A, Zarrilli F, Liguori R, Amato F, Castaldo G. Genetic diseases that predispose to early liver cirrhosis. Int J Hepatol 2014;2014:713754. [PMID: 25132997 DOI: 10.1155/2014/713754] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
27 Naehrig S, Chao CM, Naehrlich L. Cystic Fibrosis. Dtsch Arztebl Int 2017;114:564-74. [PMID: 28855057 DOI: 10.3238/arztebl.2017.0564] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
28 Jagadisan B, Srivastava A. Child with Jaundice and Pruritus: How to Evaluate? Indian J Pediatr 2016;83:1311-20. [PMID: 26932879 DOI: 10.1007/s12098-016-2058-6] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
29 Klotter V, Gunchick C, Siemers E, Rath T, Hudel H, Naehrlich L, Roderfeld M, Roeb E. Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study. PLoS One 2017;12:e0178784. [PMID: 28575039 DOI: 10.1371/journal.pone.0178784] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
30 Lee AJ, Huffmyer JL, Thiele EL, Zeitlin PL, Chatterjee D. The Changing Face of Cystic Fibrosis: An Update for Anesthesiologists. Anesth Analg 2022. [PMID: 35020677 DOI: 10.1213/ANE.0000000000005856] [Reference Citation Analysis]
31 Terlizzi V, Lucarelli M, Salvatore D, Angioni A, Bisogno A, Braggion C, Buzzetti R, Carnovale V, Casciaro R, Castaldo G, Cirilli N, Collura M, Colombo C, Di Lullo AM, Elce A, Lucidi V, Madarena E, Padoan R, Quattrucci S, Raia V, Seia M, Termini L, Zarrilli F. Clinical expression of cystic fibrosis in a large cohort of Italian siblings. BMC Pulm Med. 2018;18:196. [PMID: 30577776 DOI: 10.1186/s12890-018-0766-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
32 Martonosi ÁR, Soós A, Rumbus Z, Hegyi P, Izsák V, Pázmány P, Imrei M, Váncsa S, Szakács Z, Párniczky A. Non-invasive Diagnostic Tests in Cystic Fibrosis-Related Liver Disease: A Diagnostic Test Accuracy Network Meta-Analysis. Front Med (Lausanne) 2021;8:598382. [PMID: 34386504 DOI: 10.3389/fmed.2021.598382] [Reference Citation Analysis]
33 Cañas T, Maciá A, Muñoz-Codoceo RA, Fontanilla T, González-Rios P, Miralles M, Gómez-Mardones G. Hepatic and Splenic Acoustic Radiation Force Impulse Shear Wave Velocity Elastography in Children with Liver Disease Associated with Cystic Fibrosis. Biomed Res Int 2015;2015:517369. [PMID: 26609528 DOI: 10.1155/2015/517369] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
34 Palaniappan SK, Than NN, Thein AW, van Mourik I. Interventions for preventing and managing advanced liver disease in cystic fibrosis. Cochrane Database Syst Rev 2020;3:CD012056. [PMID: 32227478 DOI: 10.1002/14651858.CD012056.pub3] [Reference Citation Analysis]
35 Sakiani S, Kleiner DE, Heller T, Koh C. Hepatic Manifestations of Cystic Fibrosis. Clin Liver Dis 2019;23:263-77. [PMID: 30947876 DOI: 10.1016/j.cld.2018.12.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
36 Leung DH. Hepatic fibrosis scores and serum biomarkers in pediatric hepatology. Clin Liver Dis (Hoboken) 2017;9:125-30. [PMID: 30992975 DOI: 10.1002/cld.634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
37 Krzyżanowska P, Pogorzelski A, Skorupa W, Moczko J, Grebowiec P, Walkowiak J. Exogenous and endogenous determinants of vitamin K status in cystic fibrosis. Sci Rep 2015;5:12000. [PMID: 26160248 DOI: 10.1038/srep12000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
38 Sousa M, Servidoni MF, Vinagre AM, Ramalho AS, Bonadia LC, Felício V, Ribeiro MA, Uliyakina I, Marson FA, Kmit A, Cardoso SR, Ribeiro JD, Bertuzzo CS, Sousa L, Kunzelmann K, Ribeiro AF, Amaral MD. Measurements of CFTR-mediated Cl- secretion in human rectal biopsies constitute a robust biomarker for Cystic Fibrosis diagnosis and prognosis. PLoS One 2012;7:e47708. [PMID: 23082198 DOI: 10.1371/journal.pone.0047708] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
39 Poetter-Lang S, Staufer K, Baltzer P, Tamandl D, Muin D, Bastati N, Halilbasic E, Hodge JC, Trauner M, Kazemi-Shirazi L, Ba-Ssalamah A. The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study. Eur Radiol 2019;29:1048-58. [PMID: 30054796 DOI: 10.1007/s00330-018-5650-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
40 Haack A, Aragão GG, Novaes MRCG. Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases. World J Gastroenterol 2013; 19(46): 8552-8561 [PMID: 24379572 DOI: 10.3748/wjg.v19.i46.8552] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
41 Stonebraker JR, Ooi CY, Pace RG, Corvol H, Knowles MR, Durie PR, Ling SC. Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis. Clin Gastroenterol Hepatol 2016;14:1207-1215.e3. [PMID: 27062904 DOI: 10.1016/j.cgh.2016.03.041] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 9.3] [Reference Citation Analysis]
42 Rosen BH, Chanson M, Gawenis LR, Liu J, Sofoluwe A, Zoso A, Engelhardt JF. Animal and model systems for studying cystic fibrosis. J Cyst Fibros 2018;17:S28-34. [PMID: 28939349 DOI: 10.1016/j.jcf.2017.09.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
43 Cao JY, Artunduaga M, Schooler GR. Hepatic manifestations of systemic disease: an imaging-based review. Pediatr Radiol 2021. [PMID: 34797394 DOI: 10.1007/s00247-021-05222-5] [Reference Citation Analysis]
44 Fiorotto R, Amenduni M, Mariotti V, Fabris L, Spirli C, Strazzabosco M. Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy. Hepatology 2018;67:972-88. [PMID: 28836688 DOI: 10.1002/hep.29400] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
45 Jomphe V, Lands LC, Mailhot G. Nutritional Requirements of Lung Transplant Recipients: Challenges and Considerations. Nutrients 2018;10:E790. [PMID: 29921799 DOI: 10.3390/nu10060790] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
46 Lemaitre C, Dominique S, Billoud E, Eliezer M, Montialoux H, Quillard M, Riachi G, Koning E, Morisse-Pradier H, Savoye G. Relevance of 3D Cholangiography and Transient Elastography to Assess Cystic Fibrosis-Associated Liver Disease? Can Respir J. 2016;2016:4592702. [PMID: 27445541 DOI: 10.1155/2016/4592702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
47 Rath T, Hage L, Kügler M, Menendez Menendez K, Zachoval R, Naehrlich L, Schulz R, Roderfeld M, Roeb E. Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease. PLoS One. 2013;8:e58955. [PMID: 23516586 DOI: 10.1371/journal.pone.0058955] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
48 Scott J, Jones AM, Piper Hanley K, Athwal VS. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Aliment Pharmacol Ther 2022. [PMID: 35048397 DOI: 10.1111/apt.16749] [Reference Citation Analysis]
49 Olivier AK, Gibson-Corley KN, Meyerholz DK. Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology. Am J Physiol Gastrointest Liver Physiol 2015;308:G459-71. [PMID: 25591863 DOI: 10.1152/ajpgi.00146.2014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
50 Ayoub F, Li H, Blay C, Trillo-Alvarez C, Lascano J, Morelli G. Multidisciplinary Care for Cystic Fibrosis Liver Disease: Where Does the Adult Hepatologist Fit In? Clin Liver Dis (Hoboken) 2019;14:187-90. [PMID: 31879562 DOI: 10.1002/cld.845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
51 Toledano MB, Mukherjee SK, Howell J, Westaby D, Khan SA, Bilton D, Simmonds NJ. The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study. PLoS One 2019;14:e0212779. [PMID: 30947265 DOI: 10.1371/journal.pone.0212779] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
52 Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros. 2013;12:116-124. [PMID: 23266093 DOI: 10.1016/j.jcf.2012.11.010] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 9.5] [Reference Citation Analysis]
53 Polito R, Nigro E, Elce A, Monaco ML, Iacotucci P, Carnovale V, Comegna M, Gelzo M, Zarrilli F, Corso G, Castaldo G, Daniele A. Adiponectin Expression Is Modulated by Long-Term Physical Activity in Adult Patients Affected by Cystic Fibrosis. Mediators Inflamm 2019;2019:2153934. [PMID: 31582896 DOI: 10.1155/2019/2153934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
54 Rath T, Zwaschka L, Hage L, Kügler M, Menendez K, Naehrlich L, Schulz R, Roderfeld M, Roeb E. Identification of neutrophil activation markers as novel surrogate markers of CF lung disease. PLoS One 2014;9:e115847. [PMID: 25545245 DOI: 10.1371/journal.pone.0115847] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
55 Fiorotto R, Strazzabosco M. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Cell Mol Gastroenterol Hepatol 2019;8:197-207. [PMID: 31075352 DOI: 10.1016/j.jcmgh.2019.04.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
56 Kamal N, Surana P, Koh C. Liver disease in patients with cystic fibrosis. Curr Opin Gastroenterol 2018;34:146-51. [PMID: 29438119 DOI: 10.1097/MOG.0000000000000432] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
57 Enaud R, Frison E, Missonnier S, Fischer A, de Ledinghen V, Perez P, Bui S, Fayon M, Chateil JF, Lamireau T. Cystic fibrosis and noninvasive liver fibrosis assessment methods in children. Pediatr Res 2021. [PMID: 33731812 DOI: 10.1038/s41390-021-01427-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, McBennett K, Sferra TJ, Kaminski B. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-772 [PMID: 31966908 DOI: 10.4254/wjh.v11.i12.761] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
59 Lam S, Nettel-Aguirre A, Van Biervliet S, Roeb E, Sadler MD, Friedrich-Rust M, Karlas T, Kitson MT, deBruyn JCC. Transient Elastography in the Evaluation of Cystic Fibrosis-Associated Liver Disease: Systematic Review and Meta-analysis. J Can Assoc Gastroenterol 2019;2:71-80. [PMID: 31294368 DOI: 10.1093/jcag/gwy029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
60 Koh C, Sakiani S, Surana P, Zhao X, Eccleston J, Kleiner DE, Herion D, Liang TJ, Hoofnagle JH, Chernick M, Heller T. Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity. Hepatology. 2017;66:591-601. [PMID: 28422310 DOI: 10.1002/hep.29217] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 10.2] [Reference Citation Analysis]
61 Parisi GF, Di Dio G, Franzonello C, Gennaro A, Rotolo N, Lionetti E, Leonardi S. Liver disease in cystic fibrosis: an update. Hepat Mon. 2013;13:e11215. [PMID: 24171010 DOI: 10.5812/hepatmon.11215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
62 Fabris L, Fiorotto R, Spirli C, Cadamuro M, Mariotti V, Perugorria MJ, Banales JM, Strazzabosco M. Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. Nat Rev Gastroenterol Hepatol 2019;16:497-511. [PMID: 31165788 DOI: 10.1038/s41575-019-0156-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
63 Drzymała-Czyż S, Krzyżanowska-Jankowska P, Dziedzic K, Lisowska A, Kurek S, Goździk-Spychalska J, Kononets V, Woźniak D, Mądry E, Walkowiak J. Severe Genotype, Pancreatic Insufficiency and Low Dose of Pancreatic Enzymes Associate with Abnormal Serum Sterol Profile in Cystic Fibrosis. Biomolecules 2021;11:313. [PMID: 33669566 DOI: 10.3390/biom11020313] [Reference Citation Analysis]
64 Glapa-Nowak A, Mutt SJ, Lisowska A, Sapiejka E, Goździk-Spychalska J, Wieczorek-Filipiak M, Drzymała-Czyż S, Nowak JK, Thalmann O, Herzig KH, Walkowiak J. Leukocyte Telomere Length Is Not Reduced in Children and Adults with Cystic Fibrosis but Associates with Clinical Characteristics-A Cross-Sectional Study. J Clin Med 2021;10:590. [PMID: 33557298 DOI: 10.3390/jcm10040590] [Reference Citation Analysis]
65 Sasame A, Connolly L, Fitzpatrick E, Stokes D, Bourke B, Rowland M. The impact of liver disease on mortality in cystic fibrosis - a systematic review protocol. HRB Open Res 2020;3:44. [PMID: 33305166 DOI: 10.12688/hrbopenres.13065.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Paranjapye A, Ruffin M, Harris A, Corvol H. Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity. J Cyst Fibros 2020;19 Suppl 1:S10-4. [PMID: 31734115 DOI: 10.1016/j.jcf.2019.11.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
67 Sasame A, Connolly L, Fitzpatrick E, Stokes D, Bourke B, Rowland M. The impact of liver disease on mortality in cystic fibrosis - a systematic review protocol. HRB Open Res 2020;3:44. [PMID: 33305166 DOI: 10.12688/hrbopenres.13065.3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Baldissera M, Lewindon PJ, Ramm LE, Hartel GF, Mattiello R, Ramm GA. Advanced but not mild liver disease is a predictor of decreased survival in children with cystic fibrosis, with far greater impact in females: A 27-year real-life cohort study. J Cyst Fibros 2021:S1569-1993(21)02156-1. [PMID: 34949555 DOI: 10.1016/j.jcf.2021.11.015] [Reference Citation Analysis]
69 Ayoub F, Trillo-Alvarez C, Morelli G, Lascano J. Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. World J Hepatol 2018; 10(1): 34-40 [PMID: 29399276 DOI: 10.4254/wjh.v10.i1.34] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
70 Nowak JK, Sobkowiak P, Drzymała-Czyż S, Krzyżanowska-Jankowska P, Sapiejka E, Skorupa W, Pogorzelski A, Nowicka A, Wojsyk-Banaszak I, Kurek S, Zielińska-Psuja B, Lisowska A, Walkowiak J. Fat-Soluble Vitamin Supplementation Using Liposomes, Cyclodextrins, or Medium-Chain Triglycerides in Cystic Fibrosis: A Randomized Controlled Trial. Nutrients 2021;13:4554. [PMID: 34960106 DOI: 10.3390/nu13124554] [Reference Citation Analysis]
71 McBennett K, MacAskill CJ, Keshock E, Mahani MG, Mata J, Towbin AJ, Sankararaman S, Drumm ML, Yu X, Ren CL, Nasr SZ, Kutney K, Flask CA. Magnetic resonance imaging of cystic fibrosis: Multi-organ imaging in the age of CFTR modulator therapies. J Cyst Fibros 2021:S1569-1993(21)02143-3. [PMID: 34879996 DOI: 10.1016/j.jcf.2021.11.006] [Reference Citation Analysis]
72 Athwal VS, Scott JA, Fitzpatrick E, Rowland M. Emerging clinical perspectives in cystic fibrosis liver disease. Curr Opin Pulm Med 2021;27:593-9. [PMID: 34482340 DOI: 10.1097/MCP.0000000000000824] [Reference Citation Analysis]
73 Zarrilli F, Elce A, Scorza M, Giordano S, Amato F, Castaldo G. An update on laboratory diagnosis of liver inherited diseases. Biomed Res Int 2013;2013:697940. [PMID: 24222913 DOI: 10.1155/2013/697940] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
74 Staufer K. Current Treatment Options for Cystic Fibrosis-Related Liver Disease. Int J Mol Sci 2020;21:E8586. [PMID: 33202578 DOI: 10.3390/ijms21228586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
75 Ferris H, Twomey M, Moloney F, O’Neill SB, Murphy K, O’Connor OJ, Maher M. Computed tomography dose optimisation in cystic fibrosis: A review. World J Radiol 2016; 8(4): 331-341 [PMID: 27158420 DOI: 10.4329/wjr.v8.i4.331] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
76 Boëlle PY, Debray D, Guillot L, Clement A, Corvol H; French CF Modifier Gene Study Investigators. Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology 2019;69:1648-56. [PMID: 30058245 DOI: 10.1002/hep.30148] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 9.5] [Reference Citation Analysis]
77 Więcek S, Woś H, Pogorzelski A, Kordys-Darmolinska B, Mazurek H, Grzybowska-Chlebowczyk U. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis. Mediators Inflamm 2020;2020:5696185. [PMID: 32308556 DOI: 10.1155/2020/5696185] [Reference Citation Analysis]
78 Staufer K, Halilbasic E, Trauner M, Kazemi-Shirazi L. Cystic fibrosis related liver disease--another black box in hepatology. Int J Mol Sci 2014;15:13529-49. [PMID: 25093717 DOI: 10.3390/ijms150813529] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
79 Athanazio RA, Silva Filho LVRF, Vergara AA, Ribeiro AF, Riedi CA, Procianoy EDFA, Adde FV, Reis FJC, Ribeiro JD, Torres LA, Fuccio MB, Epifanio M, Firmida MC, Damaceno N, Ludwig-Neto N, Maróstica PJC, Rached SZ, Melo SFO; Grupo de Trabalho das Diretrizes Brasileiras de Diagnóstico e Tratamento da Fibrose Cística. Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. J Bras Pneumol 2017;43:219-45. [PMID: 28746534 DOI: 10.1590/S1806-37562017000000065] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
80 Hirche TO, Knoop C, Hebestreit H, Shimmin D, Solé A, Elborn JS, Ellemunter H, Aurora P, Hogardt M, Wagner TO; ECORN-CF Study Group. Practical guidelines: lung transplantation in patients with cystic fibrosis. Pulm Med 2014;2014:621342. [PMID: 24800072 DOI: 10.1155/2014/621342] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
81 Kolberg ES, Tranung M, Aasarød KM. Increased prescribing of ursodeoxycholic acid in Norway. Int J Clin Pharm 2018;40:1454-7. [PMID: 30267256 DOI: 10.1007/s11096-018-0729-2] [Reference Citation Analysis]
82 Ling SC, Ye W, Leung DH, Navarro OM, Weymann A, Karnsakul W, Freeman AJ, Magee JC, Narkewicz MR. Liver Ultrasound Patterns in Children With Cystic Fibrosis Correlate With Noninvasive Tests of Liver Disease. J Pediatr Gastroenterol Nutr 2019;69:351-7. [PMID: 31436672 DOI: 10.1097/MPG.0000000000002413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
83 Ragan H, Autry E, Bomersback T, Hewlett J, Kormelink L, Safirstein J, Shanley L, Lubsch L. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series. Pediatr Pulmonol 2021. [PMID: 34850610 DOI: 10.1002/ppul.25779] [Reference Citation Analysis]
84 Civan HA, Seyhan S. Molecular Heterogeneity in Cystic Fibrosis. J Pediatr Genet 2020;9:171-6. [PMID: 32714617 DOI: 10.1055/s-0040-1701646] [Reference Citation Analysis]
85 Terlizzi V, Di Lullo AM, Comegna M, Centrone C, Pelo E, Castaldo G, Raia V, Braggion C. S737F is a new CFTR mutation typical of patients originally from the Tuscany region in Italy. Ital J Pediatr 2018;44:2. [PMID: 29298718 DOI: 10.1186/s13052-017-0443-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
86 Al Sinani S, Al-Mulaabed S, Al Naamani K, Sultan R. Cystic Fibrosis Liver Disease: Know More. Oman Med J 2019;34:482-9. [PMID: 31745411 DOI: 10.5001/omj.2019.90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]